MX2020004202A - Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. - Google Patents
Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.Info
- Publication number
- MX2020004202A MX2020004202A MX2020004202A MX2020004202A MX2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A MX 2020004202 A MX2020004202 A MX 2020004202A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- substituted phenyl
- thiones
- triazole thiones
- sulfonyl
- Prior art date
Links
- BHAVOZDSGFLVBI-UHFFFAOYSA-N 5-[2-(benzenesulfonyl)phenyl]triazole-4-thione Chemical class C1(=CC=CC=C1)S(=O)(=O)C1=C(C=CC=C1)C=1C(N=NN=1)=S BHAVOZDSGFLVBI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579070P | 2017-10-30 | 2017-10-30 | |
| US201762584630P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/058050 WO2019089478A1 (en) | 2017-10-30 | 2018-10-29 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004202A true MX2020004202A (es) | 2020-08-13 |
Family
ID=66333645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004202A MX2020004202A (es) | 2017-10-30 | 2018-10-29 | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10501423B2 (OSRAM) |
| EP (1) | EP3703675A4 (OSRAM) |
| JP (2) | JP7277473B2 (OSRAM) |
| KR (1) | KR102639231B1 (OSRAM) |
| CN (1) | CN111372579B (OSRAM) |
| AU (1) | AU2018359224B2 (OSRAM) |
| BR (1) | BR112020008727A2 (OSRAM) |
| CA (1) | CA3080578A1 (OSRAM) |
| IL (1) | IL274010B2 (OSRAM) |
| MX (1) | MX2020004202A (OSRAM) |
| SG (1) | SG11202003879RA (OSRAM) |
| WO (1) | WO2019089478A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703675A4 (en) | 2017-10-30 | 2021-06-16 | Neuropore Therapies, Inc. | SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES |
| JP2021527692A (ja) * | 2018-06-20 | 2021-10-14 | ニューロポア セラピーズ インコーポレイテッド | Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 |
| CN117384029B (zh) * | 2023-12-12 | 2024-02-20 | 山东国邦药业有限公司 | 一种2,4,5-三氟苯乙酸的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| US4279637A (en) | 1979-06-02 | 1981-07-21 | Velsicol Chemical Corporation | Herbicidal N-substituted 4-imidazolin-2-ones |
| DE3307506A1 (de) | 1983-03-03 | 1984-09-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen |
| US5108486A (en) * | 1990-02-09 | 1992-04-28 | Kanagawa Chemical Laboratory, Ltd. | Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| US20020183306A1 (en) | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| RU2223952C2 (ru) | 2001-06-04 | 2004-02-20 | Институт физиологически активных веществ РАН | Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы |
| US20040235877A1 (en) | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| MXPA06000269A (es) | 2003-07-09 | 2006-04-07 | Hoffmann La Roche | Tiofenilaminoimidazolinas. |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| US20050228031A1 (en) | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
| US7008748B1 (en) * | 2004-09-07 | 2006-03-07 | Eastman Kodak Company | Silver salt-toner co-precipitates and imaging materials |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060217390A1 (en) | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| SG159561A1 (en) | 2005-05-09 | 2010-03-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| US20060276464A1 (en) | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| BRPI0613555A2 (pt) | 2005-07-04 | 2011-01-18 | Reddys Lab Ltd Dr | derivados de tiazóis como ativador de ampk |
| EP2543667B1 (en) | 2006-03-24 | 2015-01-28 | Array Biopharma, Inc. | A method of preparing 2-aminopyridine analogs as glucokinase activators |
| EP2081890B1 (en) | 2006-11-09 | 2011-01-12 | F. Hoffmann-La Roche AG | Arylsulfonyl pyrrolidines as 5-ht6 inhibitors |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| CA2681695A1 (en) | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| UA101166C2 (ru) | 2007-09-21 | 2013-03-11 | Аррей Биофарма Инк. | Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета |
| TW200940542A (en) | 2008-01-09 | 2009-10-01 | Array Biopharma Inc | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| JP2012518404A (ja) | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Ｃｄ１９に結合するヒト化抗体及びその使用 |
| KR102142753B1 (ko) | 2009-03-27 | 2020-09-14 | 히타치가세이가부시끼가이샤 | 열경화성 수지 조성물, 및 이를 이용한 프리프레그, 지지체 부착 절연 필름, 적층판 및 인쇄 배선판 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP6038792B2 (ja) | 2010-09-03 | 2016-12-07 | フォーマ ティーエム， エルエルシー． | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013175215A1 (en) | 2012-05-22 | 2013-11-28 | Autifony Therapeutics Limited | Triazoles as kv3 inhibitors |
| US20140044813A1 (en) | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
| EP2882726A4 (en) | 2012-08-09 | 2016-04-06 | Neuropore Therapies Inc | ARYL AND HETEROARYL-SUBSTITUTED BENZENE DERIVATIVES AS MODULATORS OF PI-3 KINASE SIGNALING PATHWAYS |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3703675A4 (en) * | 2017-10-30 | 2021-06-16 | Neuropore Therapies, Inc. | SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES |
-
2018
- 2018-10-29 EP EP18873686.2A patent/EP3703675A4/en not_active Withdrawn
- 2018-10-29 CA CA3080578A patent/CA3080578A1/en active Pending
- 2018-10-29 KR KR1020207015547A patent/KR102639231B1/ko active Active
- 2018-10-29 WO PCT/US2018/058050 patent/WO2019089478A1/en not_active Ceased
- 2018-10-29 AU AU2018359224A patent/AU2018359224B2/en not_active Ceased
- 2018-10-29 MX MX2020004202A patent/MX2020004202A/es unknown
- 2018-10-29 JP JP2020543258A patent/JP7277473B2/ja active Active
- 2018-10-29 CN CN201880071304.3A patent/CN111372579B/zh not_active Expired - Fee Related
- 2018-10-29 BR BR112020008727-0A patent/BR112020008727A2/pt not_active IP Right Cessation
- 2018-10-29 SG SG11202003879RA patent/SG11202003879RA/en unknown
-
2019
- 2019-03-27 US US16/366,793 patent/US10501423B2/en active Active
- 2019-10-24 US US16/663,054 patent/US11008294B2/en not_active Expired - Fee Related
-
2020
- 2020-04-16 IL IL274010A patent/IL274010B2/en unknown
-
2021
- 2021-04-06 US US17/223,989 patent/US11708338B2/en active Active
-
2023
- 2023-05-08 JP JP2023076473A patent/JP2023100842A/ja active Pending
- 2023-06-05 US US18/206,005 patent/US20230391734A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL274010A (en) | 2020-05-31 |
| KR102639231B1 (ko) | 2024-02-22 |
| JP7277473B2 (ja) | 2023-05-19 |
| IL274010B1 (en) | 2023-03-01 |
| US20190292158A1 (en) | 2019-09-26 |
| US10501423B2 (en) | 2019-12-10 |
| KR20200083545A (ko) | 2020-07-08 |
| US20210300881A1 (en) | 2021-09-30 |
| JP2023100842A (ja) | 2023-07-19 |
| CN111372579A (zh) | 2020-07-03 |
| JP2021501202A (ja) | 2021-01-14 |
| US11708338B2 (en) | 2023-07-25 |
| BR112020008727A2 (pt) | 2020-10-20 |
| AU2018359224A1 (en) | 2020-06-18 |
| SG11202003879RA (en) | 2020-05-28 |
| CA3080578A1 (en) | 2019-05-09 |
| US11008294B2 (en) | 2021-05-18 |
| EP3703675A1 (en) | 2020-09-09 |
| US20230391734A1 (en) | 2023-12-07 |
| AU2018359224B2 (en) | 2023-10-05 |
| WO2019089478A1 (en) | 2019-05-09 |
| EP3703675A4 (en) | 2021-06-16 |
| US20200123116A1 (en) | 2020-04-23 |
| CN111372579B (zh) | 2023-08-22 |
| IL274010B2 (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| CO2017000064A2 (es) | Compuestos de [1,2,4]triazol sustituido | |
| CL2018000070A1 (es) | Modulares de diaciglicerol aciltransderasa 2 (dgta2) | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| BR112017018276A2 (pt) | ?composição que compreende peptidase e biotensoativo e seu uso? | |
| EA201891622A1 (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| BR112018070568A2 (pt) | derivados de oxadiazol microbiocidas | |
| MX2017002295A (es) | Composiciones que comprenden una caseína y métodos para producir las mismas. | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| ECSP13012877A (es) | FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| BR112018008467A2 (pt) | derivados de oxadiazol microbiocidas | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| BR112018012825A2 (pt) | derivados de oxadiazol microbiocidas | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2018003297A (es) | Aplicador de precision. | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. |